Dr. Joel N. Saltzman
Claim this profileUHHS-Chagrin Highlands Medical Center
Studies Lung Cancer
Studies Colorectal Cancer
7 reported clinical trials
20 drugs studied
Area of expertise
1Lung Cancer
Stage III
Stage II
Stage I
2Colorectal Cancer
dMMR negative
MSI-H negative
Stage IV
Affiliated Hospitals
Clinical Trials Joel N. Saltzman is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
More about Joel N. Saltzman
Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Joel N. Saltzman has experience with
- Fluorouracil
- Gemcitabine
- Irinotecan
- Bevacizumab
- Leucovorin Calcium
- Irinotecan Hydrochloride
Breakdown of trials Joel N. Saltzman has run
Lung Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Lung Carcinoma
Anaplastic Large Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Joel N. Saltzman specialize in?
Joel N. Saltzman focuses on Lung Cancer and Colorectal Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage II.
Is Joel N. Saltzman currently recruiting for clinical trials?
Yes, Joel N. Saltzman is currently recruiting for 2 clinical trials in Beachwood Ohio. If you're interested in participating, you should apply.
Are there any treatments that Joel N. Saltzman has studied deeply?
Yes, Joel N. Saltzman has studied treatments such as Fluorouracil, Gemcitabine, Irinotecan.
What is the best way to schedule an appointment with Joel N. Saltzman?
Apply for one of the trials that Joel N. Saltzman is conducting.
What is the office address of Joel N. Saltzman?
The office of Joel N. Saltzman is located at: UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio 44122 United States. This is the address for their practice at the UHHS-Chagrin Highlands Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.